Search clinical trials for: Durvalumab

Total 756 results

Sidney Kimmel Comprehensive Cancer Center at Johns...
Fibrolamellar Cancer Foundation; Dracen Pharmaceuticals, Inc.

Recruiting

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Fibrolamellar Hepatocellular Carcinoma

United States
Georgetown University
AstraZeneca

Recruiting

Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma (ESR-22-21719)

Biliary Tract Cancer | Borderline Resectable Carcinoma

United States
AstraZeneca

Recruiting

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (TRITON)

Carcinoma, Non-Small-Cell Lung

United States
Latin American Cooperative Oncology Group
AstraZeneca

Not yet recruiting

A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil (EDUR-BRA)

Extensive-stage Small-cell Lung Cancer

Brazil
AstraZeneca
Parexel

Recruiting

BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants (PATAPSCO)

Non-Muscle- Invasive Bladder Cancer

United States
Peking Union Medical College Hospital

Recruiting

Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer

Biliary Tract Neoplasms | Immunotherapy

China
Baylor College of Medicine
Duke Cancer Institute

Not yet recruiting

Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Mesothelioma

United States
Joachim Aerts, MD PhD
AIM ImmunoTech Inc.; AstraZeneca BV

Recruiting

Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy (DURIPANC)

Metastatic Pancreatic Cancer

Netherlands
AstraZeneca

Recruiting

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (MDT-BRIDGE)

Non-small Cell Lung Cancer

Spain, Italy, France, Canada, Portugal, United States, Czechia, Germany, Sweden, Austria, Hungary
UNC Lineberger Comprehensive Cancer Center
AstraZeneca; Rgenix, Inc.

Recruiting

Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Non-Small Cell Lung Cancer

United States
Hirva Mamdani
AstraZeneca; Barbara Ann Karmanos Cancer Institute

Recruiting

MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer (MOZART)

Small Cell Lung Cancer | SCLC | Extensive Stage Small Cell Lung Cancer

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer

Advanced Lung Carcinoma

China
AstraZeneca

Recruiting

Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) (SIERRA)

Advanced Hepatocellular Carcinoma

Korea, Republic of, Italy, Spain, Vietnam, Germany, France, Japan, United States, Hong Kong, Singapore
Tianjin Medical University Cancer Institute and...

Recruiting

HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma

Unrescetable Hepatocellular Carcinoma

China
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC) (TAXIO)

Small Cell Lung Cancer Extensive Stage

France
Gruppo Oncologico del Nord-Ovest

Recruiting

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

Colorectal Cancer | Resectable Colorectal Carcinoma

Italy
Enrico De Toni

Recruiting

Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients (MONTBLANC)

Hepatocellular Carcinoma

Germany
The University of Hong Kong
Queen Mary Hospital, Hong Kong

Recruiting

Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma

Hepatocellular Carcinoma

Hong Kong
Trans Tasman Radiation Oncology Group
AstraZeneca

Recruiting

Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy (CHEST RT)

Extensive-Stage Small-Cell Lung Cancer

Australia
Filipa Lynce, MD
AstraZeneca; Daiichi Sankyo, Inc.

Recruiting

TRUDI: TDXD+Durva in HER2+/Low IBC (TRUDI)

Breast Cancer | HER2-positive Breast Cancer | Invasive Breast Cancer | Inflammatory Breast Cancer Stage III | HER2 Low Breast Adenocarcinoma

United States
AstraZeneca

Recruiting

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (TOURMALINE)

Biliary Tract Cancer

France, Spain, Italy, Korea, Republic of, Japan, United States, Germany, Singapore
Hellenic Cooperative Oncology Group

Recruiting

Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer (DRIVE)

Small-cell Lung Cancer | Extensive-stage Small-cell Lung Cancer

Greece
Indiana University

Recruiting

Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab

NSCLC, Stage III

United States
Innate Pharma

Recruiting

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

Non Small Cell Lung Cancer

France, United States, Greece, Hungary, Poland
National Taiwan University Hospital

Recruiting

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Metastatic Breast Cancer | Premenopausal Breast Cancer | ER Positive Breast Cancer

Taiwan
ETOP IBCSG Partners Foundation
Takeda

Recruiting

Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer (BOUNCE)

NSCLC, Stage III | ALK-rearrangement

France, Spain, Italy, Poland, United Kingdom
Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

Esophagus Adenocarcinoma

Germany
Lisata Therapeutics, Inc.

Recruiting

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (BOLSTER)

Cholangiocarcinoma | Bile Duct Cancer | Intrahepatic Cholangiocarcinoma | Gallbladder Carcinoma | Gallbladder Cancer | Gall Bladder Cancer | Extrahepatic Cholangiocarcinoma | Gall Bladder Carcinoma

United States, Spain
Jiping Wang, MD, PhD
AstraZeneca; Sirtex Medical

Recruiting

SIRT With Tremelimumab and Durvalumab for Resectable HCC

Hepatocellular Carcinoma | Hepatocellular Cancer | Resectable Hepatocellular Carcinoma

United States
Wake Forest University Health Sciences

Recruiting

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Nonsmall Cell Lung Cancer Stage III | Unresectable Non-Small Cell Lung Carcinoma

United States
AstraZeneca

Recruiting

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR)

NSCLC

China, United States, United Kingdom, Korea, Republic of, Italy, Hungary, Spain, Vietnam, France, Brazil, Canada, Japan, Taiwan, Germany, Austria, Turkey, India, Peru, Poland, Sweden, Bulgaria, Greece, Mexico, Denmark
Tianjin Medical University Cancer Institute and...

Recruiting

Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

Intrahepatic Cholangiocarcinoma | Durvalumab | Gemcis

China
Beijing Chest Hospital

Not yet recruiting

Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC

Extensive-stage Small-cell Lung Cancer
Spanish Cooperative Group for the Treatment of...
AstraZeneca

Recruiting

Olaparib and Durvalumab (MEDI4736) in Patients With Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations

Metastatic Pancreatic Cancer

Spain
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute; AstraZeneca; Sirtex Medical

Recruiting

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Cholangiocarcinoma | Bile Duct Cancer | Cholangiocarcinoma Non-resectable | Cholangiocarcinoma Metastatic | Metastatic Intrahepatic Cholangiocarcinoma

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Resectable Biliary Tract Cancer

China
M.D. Anderson Cancer Center
Nektar Therapeutics

Recruiting

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

Lung Cancer

United States
AstraZeneca
SWOG Clinical Trials Partnerships; Daiichi Sankyo

Recruiting

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

Breast Cancer

United States, China, Denmark, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Belgium, Spain, Japan, France, Taiwan, Greece, Brazil, Sweden, Puerto Rico
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer

Stage III Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Locally Advanced Lung Non-Small Cell Carcinoma

United States
Jeeyun Lee

Recruiting

Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

Stomach Cancer, Adenocarcinoma

Korea, Republic of
UNICANCER
AstraZeneca

Recruiting

Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax (DURVALUNG)

Small Cell Lung Carcinoma

France
IFOM ETS - The AIRC Institute of Molecular Oncology
AstraZeneca

Recruiting

Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel (ATRiBRAVE)

Triple Negative Breast Cancer Metastatic

Italy
Fondazione Ricerca Traslazionale

Recruiting

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

Non-small-cell Lung Cancer Patients

Italy
AstraZeneca

Recruiting

Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma (TREMENDOUS)

Hepatocellular Carcinoma

China
AstraZeneca
Daiichi Sankyo

Recruiting

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Endometrial Cancer | Urothelial Cancer | Biliary Tract Cancer | Metastatic Castration-resistant Prostate Cancer

Spain, China, Korea, Republic of, Canada, Italy, Poland, Turkey, United Kingdom, Japan, Taiwan, United States, France, Germany, Switzerland
Affiliated Cancer Hospital & Institute of Guangzhou...

Not yet recruiting

Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases

Lung Cancer | Radiotherapy | Extensive-stage Small-cell Lung Cancer
AstraZeneca

Recruiting

A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia (NIS durvalumab)

NSCLC, Non-small-cell Lung Carcinoma

Russian Federation
Alexander Chi

Not yet recruiting

Combining ICI With SBRT or HypoFrx-RT for ES NSCLC

Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage II

China
AHS Cancer Control Alberta

Recruiting

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Pancreatic Cancer | Cholangiocarcinoma | Biliary Tract Cancer | Hepatocellular Cancer

Canada
University Medical Center Groningen
Cambridge University Hospitals NHS Foundation Trust

Recruiting

Quantitative Fluorescence Endoscopy Using Durvalumab-680LT in Esophageal Cancer (OPTIC)

Esophageal Cancer

Netherlands

Search clinical trials for: Durvalumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations